Cryo-Cell International, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cryo-Cell International, Inc. - overview
Established
1989
Location
Oldsmar, -, US
Primary Industry
Biotechnology
About
Cryo-Cell International, Inc. specializes in cord blood and tissue banking services, focusing on the collection, processing, and preservation of umbilical cord stem cells for potential medical uses. Cryo-Cell International, Inc. provides innovative cord blood banking solutions.
Founded in 1989 by José Cohen, the company is headquartered in Florda, US, and has grown without notable pivots in its core business strategy. It has established a strong presence in the healthcare sector. Cryo-Cell® offers comprehensive cord blood and tissue banking services, focusing on the collection, processing, and storage of umbilical cord stem cells. These stem cells are increasingly recognized for their potential in treating a range of medical conditions, including autism and cerebral palsy (CP).
The company positions its services as a once-in-a-lifetime opportunity for families to safeguard their health using advanced medical technologies. Targeting expectant parents, Cryo-Cell® aims to make cord blood banking accessible through special discounts and in-house financing options. Their services are available across various international markets, emphasizing their commitment to expanding the reach of cord blood banking to families worldwide. The revenue model of Cryo-Cell® is structured around direct-to-consumer transactions, wherein families pay for cord blood and tissue banking services.
Customers typically engage in a one-time payment for the initial collection and processing of the cord blood, followed by annual storage fees for the preservation of the stem cells. This transaction structure is designed to accommodate the financial needs of families while ensuring they have continued access to their stored biological material. The company offers various pricing plans that cater to different customer needs, underscoring its goal to provide affordable options for vital health safeguarding services. In March 2026, Camac Partners acquired a 5.
3% minority stake in Cryo-Cell International, Inc. Financial terms were not disclosed.
Current Investors
Camac Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.cryo-cell.com
Verticals
HealthTech
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Cryo-Cell International, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Cryo-Cell International, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.